Michael Chiorean, MD, provides a preview of his talk on what's new in treating ulcerative colitis, including JAK inhibitors, IL-12/23 inhibitors, and other emerging agents to treat ulcerative colitis, which he will present at the virtual Advances in Inflammatory Bowel Disease 2020 regional meeting August 22.
Additional Resources:
For more information about AIBD 2020 Regionals and to register for upcoming sessions, visit https://www.aibdregionals.com.
Michael Chiorean, MD, is director of the IBD Center of Excellence at Virginia Mason Medical Center in Seattle, Washington.
TRANSCRIPT:
Dr. Michael Chiorean: Hello, and welcome to the Advances in Inflammatory Bowel Diseases, this year in a webinar format. The silver lining here is that you can watch this program from the comfort of your home or office. It's one of those activities where you don't need to wear a mask.
My name is Michael Chiorean. I'm a gastroenterologist at Virginia Mason Medical Center in Seattle. My presentation will be an overview of two of the newest and very exciting classes of therapeutics for patients with moderate to severely active ulcerative colitis, namely, JAK inhibitors and IL‑12/23 blockers.
Whenever we study a drug, or we define a drug, we have to answer several questions. First of all, how does it work? I will review the mechanism of action of these two classes of therapeutics. Then, is it going to do the job for my patients? I will review the efficacy data from the clinical trial program, but also from real‑life experience whenever available.
We're going to spend some time discussing the safety profile of these medications because these are relatively newer drugs, and how to mitigate some of the side effects that we may encounter.
Lastly, I'm going to spend some time discussing some treatment paradigms, including the positioning of these new therapeutics in the management of patients with moderately to severely active ulcerative colitis.
Sign up, get comfortable, and enjoy the show. Thank you.
